Table 2 |
|||||||||
|
Prevalence of Plasmodium falciparum trophozoites, anti-CSP antibodies and antimalarial drugs detected in children between two and nine years of age. |
|||||||||
| ID Site |
Nb of thick smears |
Prevalence of trophozoites (all species) |
Prevalence of Plasmodium falciparum trophozoites |
Prevalence of anti-CSP antibodies |
Detection of antimalarial drugs in children's urines |
||||
|
|
|
|
|
||||||
| Nb of thick smears + (%) |
Nb of thick smears + (%) |
Nb of serology |
Nb of serology + (%) |
CQ* |
PYR† |
||||
|
|
|
||||||||
| CQ+‡ |
Prevalence (95% CI) |
PYR+§ |
Prevalence (95% CI) |
||||||
|
|
|||||||||
| 1 |
100 |
26 (26.0) |
25 (25.0) |
100 |
13 (13.0) |
36 |
36.0 (26.6–46.2) |
0 |
0.0 (0.0–3.6) |
| 2 |
105 |
17 (16.2) |
17 (16.2) |
105 |
10 (9.5) |
18 |
18.0 (11.0–26.9) |
0 |
0.0 (0.0–3.6) |
| 3 |
111 |
21 (18.9) |
19 (17.1) |
110 |
13 (11.8) |
16 |
14.5 (8.5–22.5) |
0 |
0.0 (0.0–3.3) |
| 4 |
120 |
23 (19.2) |
22 (18.3) |
118 |
12 (10.2) |
56 |
47.5 (38.2–56.9) |
0 |
0.0 (0.0–3.1) |
| 5 |
101 |
54 (53.5) |
47 (46.5) |
100 |
25 (25.0) |
26 |
25.7 (17.6–35.4) |
2 |
2.0 (0.2–7.0) |
| 6 |
100 |
79 (79.0) |
72 (72.0) |
100 |
55 (55.0) |
20 |
20.0 (12.7–29.2) |
0 |
0.0 (0.0–3.6) |
| 7 |
100 |
86 (86.0) |
79 (79.0) |
100 |
48 (48.0) |
9 |
9.0 (4.2–16.4) |
0 |
0.0 (0.0–3.6) |
| 8 |
103 |
89 (86.4) |
83 (80.6) |
103 |
75 (72.8) |
14 |
14.0 (7.9–22.4) |
0 |
0.0 (0.0–3.6) |
| 9 |
84 |
60 (71.4) |
57 (67.9) |
84 |
39 (46.4) |
18 |
21.4 (13.2–31.7) |
0 |
0.0 (0.0–4.3) |
| 10 |
110 |
78 (70.9) |
66 (60.0) |
110 |
51 (46.4) |
10 |
9.1 (4.4–16.1) |
0 |
0.0 (0.0–3.3) |
| 11 |
102 |
90 (88.2) |
90 (88.2) |
104 |
93 (89.4) |
47 |
46.1 (36.2–56.2) |
1 |
1.0 (0.0–5.3) |
| 12 |
102 |
93 (91.2) |
88 (86.3) |
102 |
98 (96.1) |
33 |
33.7 (24.4–43.9) |
0 |
0.0 (0.0–3.7) |
| 13 |
102 |
41 (40.2) |
41 (40.2) |
104 |
21 (20.2) |
98 |
90.7 (83.6–95.5) |
1 |
0.9 (0.0–5.1) |
| 14 |
102 |
42 (41.2) |
38 (37.3) |
105 |
22 (21.0) |
89 |
80.2(71.5–87.1) |
0 |
0.0 (0.0–3.3) |
| 15 |
100 |
69 (69.0) |
68 (68.0) |
101 |
24 (23.8) |
60 |
61.9 (51.4–71.5) |
0 |
0.0 (0.0–3.7) |
| 16 |
117 |
100 (85.5) |
99 (84.6) |
115 |
82 (71.3) |
18 |
16.7 (10.2–25.1) |
0 |
0.0 (0.0–3.4) |
| 17 |
102 |
79 (77.5) |
78 (76.5) |
102 |
88 (86.3) |
18 |
20.0 (12.3–29.8) |
1 |
1.1 (0.0–6.0) |
| 18 |
102 |
98 (96.1) |
98 (96.1) |
105 |
93 (88.6) |
18 |
18.4 (11.3–27.5) |
0 |
0.0 (0.0–3.7) |
| 19 |
101 |
88 (87.1) |
88 (87.1) |
104 |
78 (75.0) |
31 |
31.3 (22.4–41.4) |
0 |
0.0 (0.0–3.7) |
| 20 |
104 |
55 (52.9) |
53 (51.0) |
104 |
30 (28.8) |
66 |
68.8 (58.5–77.8) |
1 |
1.0 (0.0–5.7) |
| 21 |
101 |
65 (64.4) |
55 (54.5) |
99 |
23 (23.2) |
49 |
51.0 (40.6–61.4) |
20 |
20.8 (13.2–30.3) |
| 22 |
103 |
83 (80.6) |
80 (77.7) |
66 |
25 (37.9) |
89 |
89.0 (81.2–94.4) |
0 |
0.0 (0.0–3.6) |
| 23 |
101 |
79 (78.2) |
72 (71.3 |
99 |
46 (46.5) |
35 |
34.7 (25.5–44.8) |
1 |
1.0 (0.0–5.4) |
| 24 |
101 |
65 (64.4) |
59 (58.4) |
99 |
32 (32.3) |
68 |
67.3 (57.3–76.3) |
0 |
0.0 (0.0–3.6) |
| 25 |
100 |
52 (52.0) |
41 (41.0) |
86 |
16 (18.6) |
91 |
87.5 (79.6–93.2) |
0 |
0.0 (0.0–3.5) |
| 26 |
101 |
86 (85.1) |
74 (73.3) |
102 |
29 (28.4) |
56 |
55.4 (45.2–65.3) |
0 |
0.0 (0.0–3.6) |
| 27 |
99 |
83 (83.8) |
81 (81.8) |
48 |
8 (16.7) |
28 |
27.2 (18.9–36.8) |
0 |
0.0 (0.0–3.5) |
| 28 |
104 |
87 (83.7) |
84 (80.8) |
95 |
21 (22.1) |
42 |
39.6 (30.3–49.6) |
0 |
0.0 (0.0–3.4) |
| 29 |
103 |
81 (78.6) |
76 (73.8) |
103 |
22 (21.4) |
25 |
24.3 (16.4–33.7) |
0 |
0.0 (0.0–3.5) |
| 30 |
107 |
91 (85.0) |
86 (80.4) |
107 |
34 (31.8) |
78 |
72.9 (63.4–81.0) |
2 |
1.9 (0.2–6.6) |
| Total |
3088 |
2060 (66.7) |
1936 (62.7) |
2980 |
1226 (41.1) |
1262 |
41.3 (39.6–43.0) |
29 |
1 (0.6–1.4) |
|
|
|||||||||
|
Nb: number; %, percent, *CQ: Chloroquine, † PYR: Pyrimethamine, ‡ CQ+ = number of samples with chloroquine in urine, §PYR+: number of samples with pyrimethamine in urine, Prevalence: expressed in percent. |
|||||||||
|
Gardella et al. Malaria Journal 2008 7:124 doi:10.1186/1475-2875-7-124 |
|||||||||
